ALTASCIENCES
30.5.2022 18:49:04 CEST | Business Wire | Press release
Altasciences announced today that it has been awarded a 2022 CRO Leadership Award in five categories, marking the seventh year the CRO/CDMO has been deemed a top performer by Clinical Leader and Life Science Leader.
Each year, Clinical Leader and Life Science Leader team up with ISR Reports to determine award recipients by assessing 50 CROs on more than 20 performance metrics in ISR’s annual Quality Benchmarking survey. This year, Altasciences received awards in the following categories: Capabilities, Compatibility, Expertise, Quality, and Reliability.
“Selecting the right CRO can make or break your project,” says Ed Miseta, Chief Editor for Clinical Leader. “It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for work ethic they exhibit in consistently meeting the needs of their drug development clients.”
Altasciences recognizes the importance of consistently exceeding the standards for excellence set by others in the industry, as well as their own. For more than 10 years, Altasciences has been transforming the traditional outsourcing paradigm, building a one-stop outsourcing solution that simplifies and accelerates the early phase drug development process for our partners. To that end, Altasciences is proud to have exceeded the expectations of small to large pharmaceutical companies, and will use the awards as further motivation to support educated, faster, integrated, and more complete early drug development decisions for their partners.
“To be recognized by the industry is not only an honor but a testament to the expertise of our people and the utmost care they show for both our partners and for those who seek the therapies we help develop,” says Chris Perkin, CEO at Altasciences. “To be acknowledged is a point of pride for our company, yes—but more importantly, it serves as a reminder that the more we build on our Capabilities, Compatibility, Expertise, Quality, and Reliability, the more our solutions can help our clients transform lives around the world.”
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005365/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Brings AI-Powered Quantum Error Mitigation to IBM Quantum Functions Catalog12.11.2026 06:30:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that AI-QEM, its proprietary AI-powered Quantum Error Mitigation capability, is now available in the IBM Quantum Functions Catalog. With this milestone, LTM becomes the first Global Systems Integrator (GSI) worldwide to publish a function in the catalog. The IBM Quantum Functions Catalog is an ecosystem of partner-built quantum software services that simplify quantum workflows and enable researchers and enterprises to run quantum experiments more efficiently for algorithm development and application prototyping. AI-QEM is available as a circuit function, allowing users of eligible IBM Quantum access plans to apply LTM's error mitigation capability directly within their Qiskit workflows. Quantum computers are inherently susceptible to noise and errors that can impact computational outcomes. While conventional error mitigation techniques often require additional circuit executions, quantum processing
Access Advance Announces New Effective Discount Rates for Its Multi-Codec Bridging Agreement, Starting on January 1, 202711.11.2026 20:18:00 CET | Press release
Access Advance LLC today announced that the Licensors of the HEVC Advance and VVC Advance Patent Pools have independently approved a two-step, phased reduction in the effective royalty discount available under the Multi-Codec Bridging Agreement (MCBA) for Licensees of both pools who sign the MCBA on or after January 1, 2027. Licensees that join both the HEVC Advance and VVC Advance Patent Pools and execute the MCBA on or before December 31, 2026, will secure the current MCBA rates, resulting in an effective discount of up to 50%. Licensees that sign on or after January 1, 2027 will receive a reduced discount as further described below. The MCBA is an administrative agreement, not a separate license, that lets Licensees of both HEVC Advance and VVC Advance Patent Pools pay a single, reduced royalty rate for products that include both HEVC and VVC codecs. Today the MCBA rate for a dual-codec product is the same as the VVC Advance single codec product rate; up to 50% of what a Licensee wo
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release
Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release
Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom